New neuromuscular consultant appointed to lead clinical trials as a result of DMD Hub funding

Dr Emily Whitehouse is the latest neuromuscular consultant to join the fight against DMD at the Royal Manchester Children’s Hospital (RMCH). The RMCH is part of the DMD Hub network, running clinical trials for DMD treatments. Read more

Breaking news: Duchenne UK backed drug shows success in clinical trial

Duchenne UK is delighted to announce that Vamorolone, a drug to treat Duchenne muscular dystrophy developed as an alternative to corticosteroids, has shown positive results in a Phase 2 Study. Read more

Duchenne UK funds DMD Hub Manager post for a further 4 years

Duchenne UK is committed to the ongoing success of the DMD Hub and today announced a further four years of funding for the DMD Hub Manager role, bringing total investment in the DMD Hub to £4.3million. Read more

Key Milestone: first UK patient enrolled in DMD gene therapy trial at DMD Hub site

Pfizer has announced that the first UK-based DMD patient has been enrolled in a gene therapy trial at a DMD Hub site Read more

Duchenne UK funds study to improve our knowledge of heart care in patients with DMD

Duchenne UK have funded a study that aims to improve our knowledge of treating heart muscle disease in patients with Duchenne muscular dystrophy (DMD). Read more

New clinical data for steroid-alternative drug Vamorolone announced

Pharmaceutical companies Santhera Pharmaceuticals and ReveraGen BioPharma have announced new data from their clinical study of a potential treatment for Duchenne muscular dystrophy (DMD) that could replace the current standard of care, corticosteroids. Read more

First comprehensive patient survey launched to better understand DMD care across the UK

DMD Care UK have launched the first comprehensive patient survey aiming to understand Duchenne muscular dystrophy (DMD) patients’ and caregivers’ experiences of medical care. Read more

Technology used in COVID-19 vaccine to be used for Duchenne muscular dystrophy gene therapy research

Duchenne UK has invested £287,500 into a new 18-month study investigating whether Lipid Nanoparticles (LNPs) could be used to help in gene therapy treatments for DMD. Read more

Duchenne UK and Pathfinders Neuromuscular Alliance to address lack of accessible housing for people with muscle-weakening conditions

Duchenne UK is partnering with Pathfinders Neuromuscular Alliance to address the lack of choice and control over accessible housing for people with DMD and other muscle-weakening conditions. Read more

DMD Hub used as a showcase by the National Institute for Health Research

This week we were delighted to have been featured in a publication from the National Institute for Health Research (NIHR), who have highlighted one of our major projects, the DMD Hub, as an example of how they work alongside industry to support clinical trials. Read more

Latest statement by neuromuscular clinicians: COVID vaccines are safe

A statement from four neuromuscular clinicians confirms that COVID-19 vaccines can be taken by people with DMD, and encourage those who are eligible to take it. Read more

Treatment for Duchenne muscular dystrophy accepted by Scottish Medicines Consortium

Translarna, a drug that can help treat an underlying cause of Duchenne muscular dystrophy, has been accepted for use on NHSScotland. Read more